BRPI0717206A2 - monoclonal antibody, isolated human, isolated monoclonal antibody, composition, immunoconjugate, bispecific molecule, isolated nucleic acid molecule, expression vector, host cell, transgenic mouse, hybridoma prepared from mouse, method of modulating an immune response in a subject, Method of inhibiting tumor cell growth in a subject, Method of treating an infectious disease in a subject, Method of enhancing immune response to an antigen in a subject, and Method for preparing an anti-beta antibody - Google Patents
monoclonal antibody, isolated human, isolated monoclonal antibody, composition, immunoconjugate, bispecific molecule, isolated nucleic acid molecule, expression vector, host cell, transgenic mouse, hybridoma prepared from mouse, method of modulating an immune response in a subject, Method of inhibiting tumor cell growth in a subject, Method of treating an infectious disease in a subject, Method of enhancing immune response to an antigen in a subject, and Method for preparing an anti-beta antibodyInfo
- Publication number
- BRPI0717206A2 BRPI0717206A2 BRPI0717206-0A2A BRPI0717206A BRPI0717206A2 BR PI0717206 A2 BRPI0717206 A2 BR PI0717206A2 BR PI0717206 A BRPI0717206 A BR PI0717206A BR PI0717206 A2 BRPI0717206 A2 BR PI0717206A2
- Authority
- BR
- Brazil
- Prior art keywords
- subject
- immune response
- isolated
- monoclonal antibody
- mouse
- Prior art date
Links
- 238000000034 method Methods 0.000 title 5
- 230000028993 immune response Effects 0.000 title 2
- 208000035473 Communicable disease Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000013604 expression vector Substances 0.000 title 1
- 210000004408 hybridoma Anatomy 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 238000011830 transgenic mouse model Methods 0.000 title 1
- 230000004565 tumor cell growth Effects 0.000 title 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88605806P | 2006-11-15 | 2006-11-15 | |
| PCT/US2007/084792 WO2008076560A2 (en) | 2006-11-15 | 2007-11-15 | Human monoclonal antibodies to btla and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0717206A2 true BRPI0717206A2 (en) | 2013-09-17 |
Family
ID=49123540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0717206-0A2A BRPI0717206A2 (en) | 2006-11-15 | 2007-11-15 | monoclonal antibody, isolated human, isolated monoclonal antibody, composition, immunoconjugate, bispecific molecule, isolated nucleic acid molecule, expression vector, host cell, transgenic mouse, hybridoma prepared from mouse, method of modulating an immune response in a subject, Method of inhibiting tumor cell growth in a subject, Method of treating an infectious disease in a subject, Method of enhancing immune response to an antigen in a subject, and Method for preparing an anti-beta antibody |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BRPI0717206A2 (en) |
-
2007
- 2007-11-15 BR BRPI0717206-0A2A patent/BRPI0717206A2/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201852T1 (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| BRPI0816014A2 (en) | MONOCLONAL HUMAN ANTIBODY ISOLATED, COMPOSITION, PARTNER ANTIBODY CONJUGATE, NUCLEIC ACID ISOLATED MUSCLE, EXPRESSION VECTOR, HUMAN ANTIBODY PREPARING ANTIBODY, ANTIBODY OF ANTIBODY TREATMENT OF CANCER IN AN INDIVIDUAL, ISOLATED ANTI-MESOTHELINE ANTIBODY, AND METHOD OF INHIBITING CELL GROWTH BY EXPRESSING MESOTELIN | |
| HRP20190762T1 (en) | Antibodies Bind primarily to the extracellular domain of 4 human CSF1R and their use | |
| HRP20170254T1 (en) | CD47 humanized and chimeric monoclonal antibodies | |
| HRP20200070T1 (en) | Human antibodies that bind lymphocyte activation gene-r (lag-3) and uses thereof | |
| SI2511301T1 (en) | Human antibodies to erbb 2 | |
| RU2451689C2 (en) | New antiproliferative antibodies | |
| UA105009C2 (en) | COMPOSITIONS AND METHODS INTENDED FOR THE DIRECTED INFLUENCE OF ANTIBODIES ON ANIMALS WITH PROTEIN C5 OF THE COMPLEMENT SYSTEM | |
| MY161724A (en) | Therapeutic canine immunoglobulins and methods of using the same | |
| JP2014503188A5 (en) | ||
| BRPI0210405B8 (en) | human monoclonal antibody, bispecific molecule, in vitro method to inhibit the growth of a cell expressing egfr, to induce cytolysis of a cell expressing egfr, and to detect the presence of egfr antigen or a cell expressing egfr in a sample, e, vector of expression | |
| ATE531731T1 (en) | HUMAN MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) | |
| UA116614C2 (en) | FACTOR ANTIBODY AND ITS APPLICATION | |
| HRP20160270T1 (en) | MONOCLONIC ANTIBODIES AGAINST GLIPICAN-3 | |
| CL2012002662A1 (en) | Bispecific anti-veg bivalent antibodies and a second antigen binding site that specifically binds to human ang-2; pharmaceutical composition comprising said antibody; method of treatment of a patient suffering from cancer; nucleic acid encoding said antibody, expression vector and host cell containing said nucleic acid. | |
| RU2010129045A (en) | BINDING MOLECULES TO HUMAN RECEPTOR OX40 | |
| BR112012021327B8 (en) | humanized anti-her2 monoclonal antibody, method of preparation and use thereof. | |
| JP2013523166A5 (en) | ||
| HRP20211444T1 (en) | Anti-dll3 antibody | |
| UA116194C2 (en) | ANTIBODY THAT SPECIFICALLY Binds to HUMAN ALPHA SYNUCLEIN | |
| ME02678B (en) | ANTI-OX40 ANTIBODIES AND METHOD FOR THEIR USE | |
| AR076770A1 (en) | ANTI-CD52 HUMAN IMMUNOGLOBULINS | |
| HRP20240102T1 (en) | Monoclonal antibody antagonizing and inhibiting binding between human pd-1 antigen and ligand thereof, preparation method therefor and application thereof | |
| JP2014503189A5 (en) | ||
| JP2012523848A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014. |